ArticleSkin appendage disorders2026
Hair Loss Treatments: A Google Trends Analysis Worldwide of the Past 5 Years (2018-2023).
Article in Skin appendage disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: We aimed to evaluate the recent trends in public interest regarding various alopecia-related treatments using Google Trends (GT). Method: Data generated through GT for the relative search volumes (RSVs) of the treatments-related terms were analysed: "hair loss treatment"; "minoxidil"; "oral minoxidil"; "finasteride"; "dutasteride"; "hair transplant." Analysis has been performed worldwide from July 29, 2018, to July 16, 2023. Results: Mean RSVs for "hair loss treatment" have increased since 2021 (23 ± 2.8 in 2018 to 70 ± 7.5 in 2023). Interest in "minoxidil" has been growing since 2018, with "minoxidil oral treatment" gaining attention since 2021. "Finasteride" saw a rise in 2021; "dutasteride" experienced consistent growth. RSVs for "hair transplant" have remained stable. Geographically, public interest in "hair loss treatment" was concentrated in Middle Eastern countries and Japan. Interest in oral treatments was prominent in Latin American and Spanish-speaking countries; Ireland and the UK showed strong focus on hair transplants. Conclusion: GT is not a real epidemiological tool and can be only used by individuals who have access to the Internet. We observed temporal and geographical variations in public interest in hair loss treatments. COVID-19 pandemic, differences in the prevalence of alopecia-related conditions, cultural, social influences impact search trends across countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.